Novo Nordisk A/S vs Super Micro Computer Inc — how do they compare? Novo Nordisk A/S trades at $38.63 (market cap $165.31B), while Super Micro Computer Inc trades at $41.8 (market cap $28.10B). The key difference: Novo Nordisk A/S is far larger — about 5.9× Super Micro Computer Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Super Micro Computer Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Super Micro Computer Inc for 19 Days on average.
| NVO | SMCI | |
|---|---|---|
Market Cap | $165.31B | $28.10B |
Volume | 11,432,838 | 38,581,805 |
Sector | Health | Technology |
52-Week High | $63.98 | $57.98 |
52-Week Low | $35.29 | $20.53 |
Typical Hold Time | 116 Days | 19 Days |
Enterprise Value | $179.56B | $33.56B |
Dividend Yield | 4.71% | — |
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Super Micro Computer (SMCI) trades at $41.34, down 8.03% in the last session, but maintains strong fundamental performance with consistent earnings beats and robust revenue growth projections. The stock shows bullish technical signals with support at $40 and resistance at $44, while valuation metrics remain attractive with a P/E of 13.12 and P/S of 0.76. Recent news highlights AI server demand growth and new NVIDIA Vera Rubin platform shipments.
SMCI presents a compelling value opportunity with strong AI-driven growth prospects, though investors face risks from competitive pressures and potential regulatory scrutiny. Analyst consensus leans neutral with a $42.33 price target, while institutional interest remains strong given the company's positioning in the expanding AI infrastructure market.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →Super Micro Computer, Inc., commonly known as Supermicro, is a leading provider of high-performance and high-efficiency server technology and innovation. The company specializes in designing, manufacturing, and selling advanced server, storage, and networking solutions, primarily for data centers, cloud computing, artificial intelligence, and 5G/Edge computing markets. SMCI's modular architecture allows for the rapid delivery of customized and purpose-built solutions, making it a key player in the enterprise computing and specialized AI infrastructure space.
Read more on SMCI →